Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ResMed Inc. filings document operating results, governance actions, capital returns and securities registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and fiscal-year financial results, record board-declared cash dividends and describe the treatment of NYSE common stock and ASX CHESS Depositary Interests in dividend payments.
The company’s regulatory record also covers board composition, director elections, executive officer transitions, compensation arrangements and amendments to the ResMed Inc. 2009 Incentive Award Plan. Proxy materials provide stockholder voting matters, executive compensation disclosure and corporate-governance information for the medical technology company’s public-company structure.
ResMed Inc.’s Chief Financial Officer Brett Sandercock reported his direct ownership of ResMed Common Stock. Following the reported information, he directly holds 83,495 shares of common stock. The filing reflects his updated ownership position without detailing any specific buy or sell transaction.
ResMed Inc. delivered solid growth for the quarter ended March 31, 2026. Net revenue rose to $1.43 billion from $1.29 billion, driven mainly by higher demand and unit sales in its Sleep and Breathing Health segment and steady gains in Residential Care Software.
Net income increased to $398.7 million, with diluted EPS up to $2.74 from $2.48, supported by gross margin expansion to 62.2% from 59.3%. For the first nine months, revenue reached $4.19 billion and net income $1.14 billion, reflecting broad-based growth across regions and products.
Sleep and Breathing Health generated $1.26 billion in quarterly revenue, while Residential Care Software contributed $170.9 million. ResMed ended the quarter with $1.66 billion in cash and cash equivalents and total debt of about $664.1 million, after returning capital through dividends of $0.60 per share and share repurchases.
ResMed Inc. announced a planned chief financial officer transition. Long‑tenured CFO Brett Sandercock will retire from the CFO role effective May 4, 2026 and move into special advisory positions to support Chairman and CEO Mick Farrell during the leadership handover.
The company appointed Aaron Bloomer, formerly CFO of Exact Sciences, as the new Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective May 4, 2026. His package includes a $725,000 base salary, a $150,000 sign‑on bonus, and a $3.3 million sign‑on equity grant split between restricted stock units and performance stock units.
ResMed also reported third‑quarter fiscal 2026 results and reiterated its fiscal 2026 outlook, including a gross margin range of 62–63%, SG&A expenses of 19–20%, R&D expenses of 6–7%, and an effective tax rate of 21–23%.
ResMed Inc. reported strong third-quarter fiscal 2026 results and declared a cash dividend. Net revenue was $1.43 billion, up 11% from $1.29 billion a year earlier, with GAAP net income of $398.7 million and diluted EPS of $2.74.
Non-GAAP diluted EPS was $2.86, up from $2.37. Operating cash flow for the quarter was $554.1 million, and cash and cash equivalents were $1.66 billion as of March 31, 2026. The board declared a quarterly dividend of $0.60 per share, with a record date of May 14, 2026 and payment on June 18, 2026.
ResMed Inc reports beneficial ownership by Vanguard Portfolio Management of 7,886,489 shares of Common Stock, representing 5.41% of the class. The filing states Vanguard has sole dispositive power over 7,886,489 shares and sole voting power over 22,567 shares.
ResMed Inc beneficial ownership reported by Vanguard Capital Management: 11,961,706.2 shares representing 8.21% of common stock as of 03/31/2026. The filing states these holdings reflect securities held across Vanguard funds and affiliates, with dispositive power exercised by Vanguard Capital Management LLC.
ResMed Chairman and CEO Michael J. Farrell exercised stock options and sold the resulting shares in a routine, pre-planned transaction. On April 7, 2026, he exercised options for 4,991 ResMed shares at $146.34 per share, then sold the same 4,991 shares in an open-market sale at a weighted average price of $225.5032.
The sale was conducted under a Rule 10b5-1 trading plan adopted on October 31, 2024, indicating it was pre-scheduled rather than opportunistic. After the transactions, Farrell directly holds 466,223 ResMed shares and indirectly holds 2,090 shares through the Lisette and Michael Farrell Family Trust, so the net shares sold represent a small portion of his overall stake.
Michael Farrell reported proposed sales of 4,991 shares of Common Stock on 04/07/2026 via Form 144, indicating an intended sale through Fidelity Brokerage Services LLC on the NYSE. The excerpt also lists three prior sales of 4,991 shares each on 01/07/2026, 02/09/2026, and 03/09/2026 with dollar proceeds shown for each trade.
RESMED INC Chief Financial Officer Brett Sandercock reported an open-market sale of 1,000 shares of ResMed Common Stock. The shares were sold at a price of $224.31 per share.
After this transaction, he holds 83,495 shares directly. The sale was conducted under a Rule 10b5-1 plan adopted on February 19, 2025.
ResMed Inc. director Peter C. Farrell reported an open-market sale of 2,000 shares of ResMed Common Stock at $225.00 per share. After this transaction, he directly holds 60,773 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.